Cargando…
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. PATIENTS AND METHODS: R-HCC patients who underwent T...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922827/ https://www.ncbi.nlm.nih.gov/pubmed/35287627 http://dx.doi.org/10.1186/s12885-022-09325-6 |
_version_ | 1784669572598595584 |
---|---|
author | Guo, Yusheng Ren, Yanqiao Chen, Lei Sun, Tao Zhang, Weihua Sun, Bo Zhu, Licheng Xiong, Fu Zheng, Chuansheng |
author_facet | Guo, Yusheng Ren, Yanqiao Chen, Lei Sun, Tao Zhang, Weihua Sun, Bo Zhu, Licheng Xiong, Fu Zheng, Chuansheng |
author_sort | Guo, Yusheng |
collection | PubMed |
description | PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. PATIENTS AND METHODS: R-HCC patients who underwent TACE plus camrelizumab or TACE-alone from January 2016 to August 2021 were retrospectively evaluated. Patients were assessed for tumor response, progression-free survival, survival rates and adverse events. RESULTS: Seventy-one patients were included in this study, including 20 patients in the TACE- camrelizumab group and 51 patients in the TACE-alone group. The objective response rate was 56.9% in the TACE-alone group and 40% in the TACE-camrelizumab group at 3 months (P = 0.201). The disease control rates were 84.3% in TACE-alone group and 80% in TACE-camrelizumab group at 3 months (P = 0.663). The progression-free survival (PFS) of the TACE-alone group was slightly longer than those of the TACE- camrelizumab group (9 months vs. 6 months). However, there were no statistically significant differences in the median PFS (P = 0.586). Similarly, there were no significant differences in the half-year and one-year survival rates (P = 0.304, P = 0.430). Multivariate analysis revealed that Neutrophil-to-lymphocyte ratio (NLR) was associated with PFS significantly. 75% patients developed at least one type of AEs related to camrelizumab in TACE-camrelizumab group, and no patients developed severe AEs. CONCLUSION: Comparing with TACE-Alone, the efficacy of TACE-camrelizumab for patients with R-HCC was similar. Meanwhile, the results of this study also indicated that TACE is still a better choice for patients with R-HCC. |
format | Online Article Text |
id | pubmed-8922827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89228272022-03-22 Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma Guo, Yusheng Ren, Yanqiao Chen, Lei Sun, Tao Zhang, Weihua Sun, Bo Zhu, Licheng Xiong, Fu Zheng, Chuansheng BMC Cancer Research PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. PATIENTS AND METHODS: R-HCC patients who underwent TACE plus camrelizumab or TACE-alone from January 2016 to August 2021 were retrospectively evaluated. Patients were assessed for tumor response, progression-free survival, survival rates and adverse events. RESULTS: Seventy-one patients were included in this study, including 20 patients in the TACE- camrelizumab group and 51 patients in the TACE-alone group. The objective response rate was 56.9% in the TACE-alone group and 40% in the TACE-camrelizumab group at 3 months (P = 0.201). The disease control rates were 84.3% in TACE-alone group and 80% in TACE-camrelizumab group at 3 months (P = 0.663). The progression-free survival (PFS) of the TACE-alone group was slightly longer than those of the TACE- camrelizumab group (9 months vs. 6 months). However, there were no statistically significant differences in the median PFS (P = 0.586). Similarly, there were no significant differences in the half-year and one-year survival rates (P = 0.304, P = 0.430). Multivariate analysis revealed that Neutrophil-to-lymphocyte ratio (NLR) was associated with PFS significantly. 75% patients developed at least one type of AEs related to camrelizumab in TACE-camrelizumab group, and no patients developed severe AEs. CONCLUSION: Comparing with TACE-Alone, the efficacy of TACE-camrelizumab for patients with R-HCC was similar. Meanwhile, the results of this study also indicated that TACE is still a better choice for patients with R-HCC. BioMed Central 2022-03-14 /pmc/articles/PMC8922827/ /pubmed/35287627 http://dx.doi.org/10.1186/s12885-022-09325-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Guo, Yusheng Ren, Yanqiao Chen, Lei Sun, Tao Zhang, Weihua Sun, Bo Zhu, Licheng Xiong, Fu Zheng, Chuansheng Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma |
title | Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma |
title_full | Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma |
title_fullStr | Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma |
title_full_unstemmed | Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma |
title_short | Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma |
title_sort | transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922827/ https://www.ncbi.nlm.nih.gov/pubmed/35287627 http://dx.doi.org/10.1186/s12885-022-09325-6 |
work_keys_str_mv | AT guoyusheng transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT renyanqiao transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT chenlei transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT suntao transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT zhangweihua transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT sunbo transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT zhulicheng transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT xiongfu transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma AT zhengchuansheng transarterialchemoembolizationcombinedwithcamrelizumabforrecurrenthepatocellularcarcinoma |